PMID- 37200807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240425
IS  - 2575-9108 (Electronic)
IS  - 2575-9108 (Linking)
VI  - 6
IP  - 5
DP  - 2023 May 12
TI  - Exosomal MicroRNA-223, MicroRNA-146, and MicroRNA-21 Profiles and Biochemical 
      Changes in Laryngeal Cancer.
PG  - 820-828
LID - 10.1021/acsptsci.3c00038 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is one of the most aggressive cancers, 
      and its early diagnosis is urgent. Exosomes are believed to have diagnostic 
      significance in cancer. However, the role of serum exosomal microRNAs, miR-223, 
      miR-146, and miR-21, and phosphatase and tensin homologue (PTEN) and hemoglobin 
      subunit delta (HBD) mRNAs in LSCC is unclear. Exosomes were isolated from the 
      blood serum of 10 LSCC patients and 10 healthy controls to perform scanning 
      electron microscopy and liquid chromatography quadrupole time-of-flight mass 
      spectrometry analyses to characterize them and to undergo reverse transcription 
      polymerase chain reaction to identify miR-223, miR-146, miR-21, and PTEN and HBD 
      mRNA expression phenotypes. Biochemical parameters, including serum C-reactive 
      protein (CRP) and vitamin B12, were also obtained. Serum exosomes of 10-140 nm 
      were isolated from LSCC and controls. Serum exosomal miR-223, miR-146, and PTEN 
      were found to be significantly decreased (p < 0.05), in contrast to serum 
      exosomal miRNA-21 (p < 0.01), and serum vitamin B12 and CRP (p < 0.05) were found 
      to be significantly increased, in LSCC vs controls. Our novel data show that the 
      combination of reduced serum exosomal miR-223, miR-146, and miR-21 profiles and 
      biochemical alterations in CRP and vitamin B12 levels may be useful indicators of 
      LSCC that could be validated by large studies. Our findings also suggest a 
      possible negative regulatory effect of miR-21 on PTEN in LSCC, encouraging a more 
      extensive investigation of its role.
CI  - (c) 2023 American Chemical Society.
FAU - Genc, Sidika
AU  - Genc S
AD  - Faculty of Medicine, Department of Medical Pharmacology, Bilecik Seyh Edebali 
      University, Bilecik 11230, Turkey.
FAU - Yagci, Tarik
AU  - Yagci T
AD  - Faculty of Medicine, Department of ENT, Bilecik Seyh Edebali University, Bilecik 
      11230, Turkey.
FAU - Vageli, Dimitra P
AU  - Vageli DP
AUID- ORCID: 0000-0002-9852-5790
AD  - Yale Larynx Laboratory, Department of Surgery (Otolaryngology), Yale School of 
      Medicine, New Haven, Connecticut 06510, United States.
FAU - Dundar, Riza
AU  - Dundar R
AD  - Faculty of Medicine, Department of ENT, Bilecik Seyh Edebali University, Bilecik 
      11230, Turkey.
FAU - Doukas, Panagiotis G
AU  - Doukas PG
AD  - Yale Larynx Laboratory, Department of Surgery (Otolaryngology), Yale School of 
      Medicine, New Haven, Connecticut 06510, United States.
FAU - Doukas, Sotirios G
AU  - Doukas SG
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Saint Peter University Hospital, New Brunswick New Jersey 08901-1780, United 
      States.
AD  - Department of Forensic Sciences and Toxicology, Faculty of Medicine, University 
      of Crete, 71003 Heraklion, Greece.
FAU - Tolia, Maria
AU  - Tolia M
AD  - Department of Radiology, Faculty of Medicine, University of Crete, 71003 
      Heraklion, Greece.
FAU - Chatzakis, Nikolaos
AU  - Chatzakis N
AD  - Otorhinolaryngologist Consultant, ENT Department of University Hospital of Crete, 
      71003 Heraklion, Greece.
FAU - Tsatsakis, Aristidis
AU  - Tsatsakis A
AD  - Department of Forensic Sciences and Toxicology, Faculty of Medicine, University 
      of Crete, 71003 Heraklion, Greece.
FAU - Taghizadehghalehjoughi, Ali
AU  - Taghizadehghalehjoughi A
AD  - Faculty of Medicine, Department of Medical Pharmacology, Bilecik Seyh Edebali 
      University, Bilecik 11230, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230424
PL  - United States
TA  - ACS Pharmacol Transl Sci
JT  - ACS pharmacology & translational science
JID - 101721411
PMC - PMC10186621
COIS- The authors declare no competing financial interest.
EDAT- 2023/05/18 19:12
MHDA- 2023/05/18 19:13
PMCR- 2024/04/24
CRDT- 2023/05/18 16:46
PHST- 2023/02/23 00:00 [received]
PHST- 2023/05/18 19:13 [medline]
PHST- 2023/05/18 19:12 [pubmed]
PHST- 2023/05/18 16:46 [entrez]
PHST- 2024/04/24 00:00 [pmc-release]
AID - 10.1021/acsptsci.3c00038 [doi]
PST - epublish
SO  - ACS Pharmacol Transl Sci. 2023 Apr 24;6(5):820-828. doi: 
      10.1021/acsptsci.3c00038. eCollection 2023 May 12.